Moderna Gets Emergency Use Approval for COVID Vaccines

The rest of the story, as the saying goes, is history. December 12, 2019, Amy Petrick, Ph.D., NIAID’s technology transfer specialist, signed the agreement, along with Dr. Barney Graham, an investigator for NIAID, whose signature is undated.8 May 12, 2020, just months later, Moderna was granted a fast-track designation for its mRNA-1273 vaccine by the U.S. Food and Drug Administration. According to Moderna’s news release:9

“mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), a part of the NIH.”

December 18, 2020 — about one year after the material transfer agreement was signed — the FDA issued emergency use authorization for Moderna’s COVID-19 vaccine for use in individuals 18 years of age and older.10 June 10, 2021, Moderna also filed for emergency use authorization for its COVID-19 shot to be used in U.S. adolescents aged 12 to 17 years.11 Yet, we still have no answers to some glaring questions:12

“It was not until January 9th 2020 that the WHO reported13 Chinese authorities had determined the outbreak was due to a novel coronavirus which later became known as SARS-CoV-2 with the alleged resultant disease dubbed COVID-19. So why was an mRNA coronavirus vaccine candidate developed by Moderna being transferred to the University of North Carolina on December 12th 2019?

… Perhaps Moderna and the National Institute of Allergy and Infectious Diseases would like to explain themselves in a court of law?”

Read More

redditpinterestlinkedintumblrmail